Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
SupplySide West 2024SupplySide West 2024
Not Confirmed
Not Confirmed
28 October-01 November, 2024
World Vaccine CongressWorld Vaccine Congress
Not Confirmed
Not Confirmed
28-31 October, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
SupplySide West 2024SupplySide West 2024
Industry Trade Show
Not Confirmed
28 October-01 November, 2024
World Vaccine CongressWorld Vaccine Congress
Industry Trade Show
Not Confirmed
28-31 October, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/due-to-its-20-year-mastery-in-micronization-inke-has-emerged-a-cornerstone-in-treating-global-respiratory-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions
29 Oct 2024
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/after-prior-trial-flop-eyepoint-redeems-lead-candidate-duravyu-promising-diabetic-macular
29 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/30/2971359/0/en/EyePoint-Pharmaceuticals-Announces-Pricing-of-Upsized-Public-Offering.html
28 Oct 2024
// #N/A
https://www.globenewswire.com/news-release/2024/10/28/2970394/0/en/EyePoint-Pharmaceuticals-Announces-Proposed-Public-Offering-of-Common-Stock.html
24 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/10/24/2968541/0/en/EyePoint-Pharmaceuticals-Announces-First-Patient-Dosed-in-Global-Phase-3-LUGANO-Clinical-Trial-of-DURAVYUTM-for-the-Treatment-of-Wet-Age-Related-Macular-Degeneration.html
16 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/16/2963896/0/en/EyePoint-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html
16 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/16/2946506/0/en/EyePoint-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html
Details:
The intends to use the net proceeds from the offering to advance clinical development of Duravyu (Vorolanib) for wet age related macular degeneration (wet AMD) and diabetic macular edema.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Brand Name: Duravyu
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: J.P. Morgan
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering October 28, 2024
Lead Product(s) : Vorolanib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : Undisclosed
Deal Type : Public Offering
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
Details : The intends to use the net proceeds from the offering to advance clinical development of Duravyu (Vorolanib) for wet age related macular degeneration (wet AMD) and diabetic macular edema.
Brand Name : Duravyu
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 28, 2024
Details:
Duravyu delivers vorolanib, a selective TKI in a bioerodible insert using EyePoint’s Durasert E™ technology, under phase 2 development for treating non-proliferative diabetic retinopathy.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Brand Name: Duravyu
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2024
Lead Product(s) : Vorolanib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EyePoint Pharmaceuticals Reports Topline Data from Phase 2 PAVIA Trial Of DURAVYU™
Details : Duravyu delivers vorolanib, a selective TKI in a bioerodible insert using EyePoint’s Durasert E™ technology, under phase 2 development for treating non-proliferative diabetic retinopathy.
Brand Name : Duravyu
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 06, 2024
Details:
EYP-1901 delivers vorolanib, a tyrosine kinase inhibitor formulated in a bioerodible insert using EyePoint's Durasert E™ technology. It is in phase 2 trials for treating diabetic macular edema.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Brand Name: EYP-1901
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Lead Product(s) : Vorolanib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 Verona Trial
Details : EYP-1901 delivers vorolanib, a tyrosine kinase inhibitor formulated in a bioerodible insert using EyePoint's Durasert E™ technology. It is in phase 2 trials for treating diabetic macular edema.
Brand Name : EYP-1901
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 10, 2024
Details:
EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, for wet age related macular degeneration.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Brand Name: EYP-1901
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: J.P. Morgan
Deal Size: $230.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 08, 2023
Lead Product(s) : Vorolanib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $230.0 million
Deal Type : Public Offering
Details : EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, for wet age related macul...
Brand Name : EYP-1901
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 08, 2023
Details:
EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, for wet age related macular degeneration.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Brand Name: EYP-1901
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: J.P. Morgan
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 05, 2023
Lead Product(s) : Vorolanib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $200.0 million
Deal Type : Public Offering
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering
Details : EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, for wet age related macul...
Brand Name : EYP-1901
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 05, 2023
Details:
EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, for wet age related macular degeneration.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Brand Name: EYP-1901
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: J.P. Morgan
Deal Size: $201.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 04, 2023
Lead Product(s) : Vorolanib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $201.2 million
Deal Type : Public Offering
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
Details : EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, for wet age related macul...
Brand Name : EYP-1901
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 04, 2023
Details:
EYP-1901 (vorolanib) is being developed as a sustained delivery treatment for wet age-related macular degeneration combining a bioerodible formulation of EyePoint's proprietary Durasert® delivery technology (Durasert E™) with vorolanib, a tyrosine kinase inhibitor.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Brand Name: EYP-1901
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Lead Product(s) : Vorolanib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : EYP-1901 (vorolanib) is being developed as a sustained delivery treatment for wet age-related macular degeneration combining a bioerodible formulation of EyePoint's proprietary Durasert® delivery technology (Durasert E™) with vorolanib, a tyrosine kin...
Brand Name : EYP-1901
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 11, 2023
Details:
Through the divestment, Alimera will receive global rights to YUTIQ outside of China, Hong Kong, Taiwan, Macau and Southeast Asia. YUTIQ® (fluocinolone acetonide) is indicated for the treatment of chronic, non-infectious uveitis affecting the posterior segment of the eye.
Lead Product(s): Fluocinolone Acetonide
Therapeutic Area: Ophthalmology Brand Name: Yutiq
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Alimera Sciences
Deal Size: $82.5 million Upfront Cash: $75.0 million
Deal Type: Divestment May 18, 2023
Lead Product(s) : Fluocinolone Acetonide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Alimera Sciences
Deal Size : $82.5 million
Deal Type : Divestment
EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cas...
Details : Through the divestment, Alimera will receive global rights to YUTIQ outside of China, Hong Kong, Taiwan, Macau and Southeast Asia. YUTIQ® (fluocinolone acetonide) is indicated for the treatment of chronic, non-infectious uveitis affecting the posterior ...
Brand Name : Yutiq
Molecule Type : Small molecule
Upfront Cash : $75.0 million
May 18, 2023
Details:
EYP-1901 (vorolanib) is being developed as an investigational sustained delivery, for maintenance treatment of wet AMD combining a bioerodible formulation of Durasert® delivery technology with vorolanib, a tyrosine kinase inhibitor.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Brand Name: EYP-1901
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Lead Product(s) : Vorolanib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : EYP-1901 (vorolanib) is being developed as an investigational sustained delivery, for maintenance treatment of wet AMD combining a bioerodible formulation of Durasert® delivery technology with vorolanib, a tyrosine kinase inhibitor.
Brand Name : EYP-1901
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 27, 2023
Details:
The partnership will evaluate sustained delivery of Rallybio’s inhibitor of complement component 5 using EyePoint’s proprietary Durasert technology for sustained intraocular drug delivery. RLYB114 is a C5-targeted Affibody® molecule conjugated to polyethylene glycol (PEG).
Lead Product(s): RLYB114
Therapeutic Area: Ophthalmology Brand Name: RLYB114
Study Phase: PreclinicalProduct Type: Peptide
Sponsor: Rallybio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 27, 2023
Lead Product(s) : RLYB114
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Rallybio
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The partnership will evaluate sustained delivery of Rallybio’s inhibitor of complement component 5 using EyePoint’s proprietary Durasert technology for sustained intraocular drug delivery. RLYB114 is a C5-targeted Affibody® molecule conjugated to po...
Brand Name : RLYB114
Molecule Type : Peptide
Upfront Cash : Undisclosed
February 27, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?